TABLE 2.
(Mean ± SE) | |||||
---|---|---|---|---|---|
2w | 4w | 8w | 12w | ||
Aberrant morae | BT | −9.9 ± 2.66 b | −7.0 ± 2.30 a | −6.3 ± 1.90 a | −3.5 ± 1.42 a |
Placebo | −1.1 ± 0.68 | −0.2 ± 0.46 | −0.3 ± 0.62 | 0.4 ± 0.43 | |
(S) in GRBAS | BT | −1.18 ± 0.33 b | −0.91 ± 0.37 a | −0.73 ± 0.36 a | −0.36 ± 0.24 |
Placebo | −0.18 ± 0.18 | −0.27 ± 0.36 | −0.00 ± 0.19 | −0.27 ± 0.30 | |
VHI | BT | −14.6 ± 7.35 | −24.0 ± 9.63 a | −20.6 ± 9.91 a | −16.7 ± 7.59 a |
Placebo | −9.8 ± 3.32 | −5.3 ± 3.43 | −8.0 ± 3.52 | −5.7 ± 4.90 | |
VAS | BT | −11.6 ± 8.67 | −20.5 ± 8.74 | −18.6 ± 10.53 | −15.6 ± 8.68 |
Placebo | −2.0 ± 4.09 | −6.2 ± 4.67 | −0.2 ± 4.70 | −3.2 ± 3.95 |
Abbreviations: BT, botulinum toxin; VHI, Voice Handicap Index; VAS, visual analogue scale.
<0.05 (vs baseline).
<0.01 (vs baseline).